BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miyakawa H, Tanaka A, Kikuchi K, Matsushita M, Kitazawa E, Kawaguchi N, Fujikawa H, Gershwin ME. Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. Hepatology. 2001;34:243-248. [PMID: 11481607 DOI: 10.1053/jhep.2001.26514] [Cited by in Crossref: 144] [Cited by in F6Publishing: 131] [Article Influence: 6.9] [Reference Citation Analysis]
Number Citing Articles
1 Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. Lancet. 2011;377:1600-1609. [PMID: 21529926 DOI: 10.1016/s0140-6736(10)61965-4] [Cited by in Crossref: 193] [Cited by in F6Publishing: 85] [Article Influence: 17.5] [Reference Citation Analysis]
2 Kawai T, Hosoya N, Moritoki Y, Kajiyama Y, Watanabe M, Takai A, Selmi C, Gershwin ME, Miyakawa H, Kikuchi K. Autoantibody IgG subclasses to recombinant antigens and the role of bacterial stimuli in primary biliary cirrhosis. Hepatology Research 2009;39:874-81. [DOI: 10.1111/j.1872-034x.2009.00533.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Muratori P, Muratori L, Ferrari R, Cassani F, Bianchi G, Lenzi M, Rodrigo L, Linares A, Fuentes D, Bianchi FB. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol. 2003;98:431-437. [PMID: 12591064 DOI: 10.1111/j.1572-0241.2003.07257.x] [Cited by in Crossref: 145] [Cited by in F6Publishing: 129] [Article Influence: 7.6] [Reference Citation Analysis]
4 Villalta D, Seaman A, Tiongson M, Warren C, Bentow C, Bizzaro N, Alessio MG, Porcelli B, Norman GL, Mahler M. Evaluation of a novel extended automated particle-based multi-analyte assay for the detection of autoantibodies in the diagnosis of primary biliary cholangitis. Clin Chem Lab Med 2020;58:1499-507. [PMID: 32286240 DOI: 10.1515/cclm-2020-0122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
5 Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009;50:291-308. [PMID: 19554543 DOI: 10.1002/hep.22906] [Cited by in Crossref: 850] [Cited by in F6Publishing: 705] [Article Influence: 65.4] [Reference Citation Analysis]
6 Stone J, Wade JA, Cauch-Dudek K, Ng C, Lindor KD, Heathcote EJ. Human leukocyte antigen Class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis. J Hepatol. 2002;36:8-13. [PMID: 11804658 DOI: 10.1016/S0168-8278(01)00237-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
7 Gisbert JP, Jones EA, Pajares JM, Moreno-otero R. Is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)?: REVIEW: TREATMENT OF AUTOIMMUNE CHOLANGITIS. Alimentary Pharmacology & Therapeutics 2003;17:17-27. [DOI: 10.1046/j.1365-2036.2003.01381.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
8 Cuperus FJ, Halilbasic E, Trauner M. Fibrate treatment for primary biliary cirrhosis. Curr Opin Gastroenterol. 2014;30:279-286. [PMID: 24625898 DOI: 10.1097/mog.0000000000000056] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
9 Hazama H, Omagari K, Masuda J, Ohba K, Kinoshita H, Matsuo I, Isomoto H, Mizuta Y, Murase K, Murata I, Kohno S. Automated enzymatic mitochondrial antibody assay for the diagnosis of primary biliary cirrhosis: Applications of a routine diagnostic tool for the detection of antimitochondrial antibodies. J Gastroenterol Hepatol 2002;17:316-23. [DOI: 10.1046/j.1440-1746.2002.02700.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
10 Washington MK. Autoimmune liver disease: overlap and outliers. Mod Pathol. 2007;20 Suppl 1:S15-S30. [PMID: 17486048 DOI: 10.1038/modpathol.3800684] [Cited by in Crossref: 64] [Cited by in F6Publishing: 48] [Article Influence: 4.3] [Reference Citation Analysis]
11 Norman GL, Reig A, Viñas O, Mahler M, Wunsch E, Milkiewicz P, Swain MG, Mason A, Stinton LM, Aparicio MB, Aldegunde MJ, Fritzler MJ, Parés A. The Prevalence of Anti-Hexokinase-1 and Anti-Kelch-Like 12 Peptide Antibodies in Patients With Primary Biliary Cholangitis Is Similar in Europe and North America: A Large International, Multi-Center Study. Front Immunol 2019;10:662. [PMID: 31001269 DOI: 10.3389/fimmu.2019.00662] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
12 Neuberger J. Antibodies and primary biliary cirrhosis – piecing together the jigsaw. Journal of Hepatology 2002;36:126-9. [DOI: 10.1016/s0168-8278(01)00303-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
13 Lleo A, Selmi C, Invernizzi P, Podda M, Coppel RL, Mackay IR, Gores GJ, Ansari AA, Van de Water J, Gershwin ME. Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology. 2009;49:871-879. [PMID: 19185000 DOI: 10.1002/hep.22736] [Cited by in Crossref: 150] [Cited by in F6Publishing: 131] [Article Influence: 11.5] [Reference Citation Analysis]
14 Koutsoumpas AL, Kriese S, Rigopoulou EI. Popular and unpopular infectious agents linked to primary biliary cirrhosis. Auto Immun Highlights 2012;3:95-104. [PMID: 26000132 DOI: 10.1007/s13317-012-0039-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Ronca V, Chen QB, Lygoura V, Ben‐mustapha I, Shums Z, Trifa M, Carbone M, Mancuso C, Milani C, Bernuzzi F, Ma X, Agrebi N, Norman GL, Chang C, Gershwin ME, Barbouche M, Invernizzi P. Autoantibodies in patients with interleukin 12 receptor beta 1 deficiency. J Dig Dis 2019;20:363-70. [DOI: 10.1111/1751-2980.12790] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Bizzaro N, Covini G, Rosina F, Muratori P, Tonutti E, Villalta D, Pesente F, Alessio MG, Tampoia M, Antico A, Platzgummer S, Porcelli B, Terzuoli L, Liguori M, Bassetti D, Brusca I, Almasio PL, Tarantino G, Bonaguri C, Agostinis P, Bredi E, Tozzoli R, Invernizzi P, Selmi C. Overcoming a “Probable” Diagnosis in Antimitochondrial Antibody Negative Primary Biliary Cirrhosis: Study of 100 Sera and Review of the Literature. Clinic Rev Allerg Immunol 2012;42:288-97. [DOI: 10.1007/s12016-010-8234-y] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
17 Deltenre P, Henrion J, Canva V, Dharancy S, Texier F, Louvet A, De Maeght S, Paris JC, Mathurin P. Evaluation of amantadine in chronic hepatitis C: a meta-analysis. J Hepatol. 2004;41:462-473. [PMID: 15336450 DOI: 10.1016/j.jhep.2004.05.019] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 3.3] [Reference Citation Analysis]
18 Mayo MJ. Primary biliary cirrhosis: the future. Clin Liver Dis. 2003;7:957-969. [PMID: 14594140 DOI: 10.1016/s1089-3261(03)00093-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Omagari K, Hazama H, Kohno S. Enzyme inhibition assay for pyruvate dehydrogenase complex: Clinical utility for the diagnosis of primary biliary cirrhosis. World J Gastroenterol 2005; 11(43): 6735-6739 [PMID: 16425376 DOI: 10.3748/wjg.v11.i43.6735] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
20 Hirschfield GM, Heathcote EJ. Antimitochondrial antibody-negative primary biliary cirrhosis. Clin Liver Dis. 2008;12:323-331; viii-ix. [PMID: 18456183 DOI: 10.1016/j.cld.2008.02.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
21 Selmi C, Coppel RL, Gershwin ME. Primary Biliary Cirrhosis. The Autoimmune Diseases. Elsevier; 2006. pp. 749-65. [DOI: 10.1016/b978-012595961-2/50057-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Shimoda S, Tsuneyama K, Kikuchi K, Harada K, Nakanuma Y, Nakamura M, Ishibashi H, Hisamoto S, Niiro H, Leung PS. The role of natural killer (NK) and NK T cells in the loss of tolerance in murine primary biliary cirrhosis. Clin Exp Immunol. 2012;168:279-284. [PMID: 22519590 DOI: 10.1111/j.1365-2249.2012.04581.x.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Rong G, Zhong R, Lleo A, Leung PS, Bowlus CL, Yang GX, Yang CY, Coppel RL, Ansari AA, Cuebas DA. Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis. Hepatology. 2011;54:196-203. [PMID: 21488079 DOI: 10.1002/hep.24355] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]
24 Olafsson S, Gudjonsson H, Selmi C, Amano K, Invernizzi P, Podda M, Gershwin ME. Antimitochondrial antibodies and reactivity to N. aromaticivorans proteins in Icelandic patients with primary biliary cirrhosis and their relatives. Am J Gastroenterol. 2004;99:2143-2146. [PMID: 15554994 DOI: 10.1111/j.1572-0241.2004.40397.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
25 Neuberger J, Bradwell AR. Walker JG, Doniach D, Roitt IM, Sherlock S. Serological tests in diagnosis of primary biliary cirrhosis [Lancet 1965;i:827–831]. Journal of Hepatology 2002;37:712-6. [DOI: 10.1016/s0168-8278(02)00322-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
26 Nezu S, Tanaka A, Yasui H, Imamura M, Nakajima H, Ishida H, Takahashi S. Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis. J Gastroenterol Hepatol 2006;0:060606032707024-???. [DOI: 10.1111/j.1440-1746.2006.04434.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 21] [Article Influence: 0.3] [Reference Citation Analysis]
27 Dantzler TE, Lawitz EJ. Treatment of chronic hepatitis C in nonresponders to previous therapy. Curr Gastroenterol Rep 2003;5:78-85. [DOI: 10.1007/s11894-003-0013-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
28 Selmi C, Zuin M, Gershwin ME. The unfinished business of primary biliary cirrhosis. J Hepatol 2008;49:451-60. [PMID: 18640737 DOI: 10.1016/j.jhep.2008.06.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
29 Sakauchi F, Mori M, Zeniya M, Toda G. Antimitochondrial antibody negative primary biliary cirrhosis in Japan: utilization of clinical data when patients applied to receive public financial aid. J Epidemiol. 2006;16:30-34. [PMID: 16369106 DOI: 10.2188/jea.16.30] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
30 Burt AD. Primary biliary cirrhosis and other ductopenic diseases. Clin Liver Dis. 2002;6:363-80, vi. [PMID: 12122861 DOI: 10.1016/s1089-3261(02)00010-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
31 Bonkovsky HL. Iron as a comorbid factor in chronic viral hepatitis. Am J Gastroenterol. 2002;97:1-4. [PMID: 11808931 DOI: 10.1111/j.1572-0241.2002.05390.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 2.3] [Reference Citation Analysis]
32 Selmi C, Invernizzi P, Zuin M, Podda M, Seldin MF, Gershwin ME. Genes and (auto)immunity in primary biliary cirrhosis. Genes Immun. 2005;6:543-556. [PMID: 16034472 DOI: 10.1038/sj.gene.6364248] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
33 Invernizzi P, Alessio MG, Smyk DS, Lleo A, Sonzogni A, Fabris L, Candusso M, Bogdanos DP, Iorio R, Torre G. Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature. BMC Gastroenterol 2012;12:92. [PMID: 22816667 DOI: 10.1186/1471-230X-12-92] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
34 Czaja AJ, Norman GL. Autoantibodies in the diagnosis and management of liver disease. J Clin Gastroenterol 2003;37:315-29. [PMID: 14506390 DOI: 10.1097/00004836-200310000-00011] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
35 Shimoda S, Tsuneyama K, Kikuchi K, Harada K, Nakanuma Y, Nakamura M, Ishibashi H, Hisamoto S, Niiro H, Leung PS. The role of natural killer (NK) and NK T cells in the loss of tolerance in murine primary biliary cirrhosis. Clin Exp Immunol. 2012;168:279-284. [PMID: 22519590 DOI: 10.1111/j.1365-2249.2012.04581.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
36 Czaja AJ. Autoimmune liver disease: . Current Opinion in Gastroenterology 2002;18:334-44. [DOI: 10.1097/00001574-200205000-00007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
37 Heathcote J. Variant syndromes of autoimmune hepatitis. Clinics in Liver Disease 2002;6:669-84. [DOI: 10.1016/s1089-3261(02)00031-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
38 Maeda MH, Tsuji S, Shimizu J. Inflammatory myopathies associated with anti-mitochondrial antibodies. Brain 2012;135:1767-77. [DOI: 10.1093/brain/aws106] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
39 Muratori L, Granito A, Muratori P, Pappas G, Bianchi FB. Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value. Clin Liver Dis. 2008;12:261-276; vii. [PMID: 18456179 DOI: 10.1016/j.cld.2008.02.009] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
40 Berg CP, Stein GM, Klein R, Pascu M, Berg T, Kammer W, Priemer M, Nordheim A, Schulze-osthoff K, Gregor M, Wesselborg S, Berg PA. Demonstration of PDC-E1 subunits as major antigens in the complement-fixing fraction M4 and re-evaluation of PDC-E1-specific antibodies in PBC patients. Liver Int 2006;26:846-55. [DOI: 10.1111/j.1478-3231.2006.01303.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
41 Jiang XH, Zhong RQ, Fan XY, Hu Y, An F, Sun JW, Kong XT. Characterization of M2 antibodies in asymptomatic Chinese population. World J Gastroenterol 2003; 9(9): 2128-2131 [PMID: 12970922 DOI: 10.3748/wjg.v9.i9.2128] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
42 Bogdanos DP, Baum H, Vergani D. Antimitochondrial and other autoantibodies. Clin Liver Dis. 2003;7:759-777. [PMID: 14594130 DOI: 10.1016/s1089-3261(03)00104-1] [Cited by in Crossref: 71] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
43 Yin YF, Zhang X. B cell depletion in treating primary biliary cirrhosis: Pros and cons. World J Gastroenterol 2012; 18(30): 3938-3940 [PMID: 22912543 DOI: 10.3748/wjg.v18.i30.3938] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
44 Cornberg M, Hinrichsen H, Teuber G, Berg T, Naumann U, Falkenberg C, Zeuzem S, Manns MP. Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C. J Hepatol 2002;37:843-7. [PMID: 12445427 DOI: 10.1016/s0168-8278(02)00300-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
45 Purohit T, Cappell MS. Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy. World J Hepatol 2015; 7(7): 926-941 [PMID: 25954476 DOI: 10.4254/wjh.v7.i7.926] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
46 Selmi C, Balkwill DL, Invernizzi P, Ansari AA, Coppel RL, Podda M, Leung PS, Kenny TP, Van De Water J, Nantz MH, Kurth MJ, Gershwin ME. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology. 2003;38:1250-1257. [PMID: 14578864 DOI: 10.1053/jhep.2003.50446] [Cited by in Crossref: 219] [Cited by in F6Publishing: 186] [Article Influence: 11.5] [Reference Citation Analysis]
47 Moreno-otero R. Therapeutic modalities in hepatitis C: challenges and development. J Viral Hepat 2005;12:10-9. [DOI: 10.1111/j.1365-2893.2005.00563.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
48 Kawata K, Kobayashi Y, Gershwin ME, Bowlus CL. The Immunophysiology and Apoptosis of Biliary Epithelial Cells: Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clin Rev Allergy Immunol. 2012; Jun 12. [Epub ahead of print]. [PMID: 22689287 DOI: 10.1007/s12016-012-8324-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
49 Nguyen HH, Khathlan A, Fritzler MJ, Swain MG. A case series evaluating the impact of Hepatitis C eradication using direct acting antivirals on primary biliary cholangitis-associated autoimmunity. BMC Gastroenterol 2018;18:97. [PMID: 29940867 DOI: 10.1186/s12876-018-0826-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
50 Selmi C, Ross SR, Ansari AA, Invernizzi P, Podda M, Coppel RL, Gershwin M. Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. Gastroenterology 2004;127:493-501. [DOI: 10.1053/j.gastro.2004.05.033] [Cited by in Crossref: 85] [Cited by in F6Publishing: 70] [Article Influence: 4.7] [Reference Citation Analysis]
51 Gane E. Treatment of recurrent hepatitis C. Liver Transpl. 2002;8:S28-S37. [PMID: 12362295 DOI: 10.1053/jlts.2002.35860] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
52 Washington MK, Manns MP. Autoimmune hepatitis. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 467-90. [DOI: 10.1016/b978-0-7020-3398-8.00009-x] [Cited by in Crossref: 7] [Article Influence: 0.7] [Reference Citation Analysis]
53 Hu CJ, Song G, Huang W, Liu GZ, Deng CW, Zeng HP, Wang L, Zhang FC, Zhang X, Jeong JS. Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays. Mol Cell Proteomics. 2012;11:669-680. [PMID: 22647870 DOI: 10.1074/mcp.m111.015529] [Cited by in Crossref: 62] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
54 Selmi C, Zuin M, Bowlus CL, Gershwin ME. Anti-mitochondrial antibody-negative primary biliary cirrhosis. Clin Liver Dis. 2008;12:173-185, ix. [PMID: 18242503 DOI: 10.1016/j.cld.2007.11.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
55 Watanabe N, Takashimizu S, Shiraishi K, Kagawa T, Nishizaki Y, Mine T, Akatsuka A, Selmi C, Gershwin ME. Primary biliary cirrhosis with multinucleated hepatocellular giant cells: implications for pathogenesis of primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2006;18:1023-7. [PMID: 16894319 DOI: 10.1097/01.meg.0000230082.60921.be] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
56 Cavazzana I, Ceribelli A, Taraborelli M, Fredi M, Norman G, Tincani A, Satoh M, Franceschini F. Primary Biliary Cirrhosis-related Autoantibodies in a Large Cohort of Italian Patients with Systemic Sclerosis. J Rheumatol 2011;38:2180-5. [DOI: 10.3899/jrheum.110167] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
57 Worman HJ. Nuclear envelope protein autoantigens in primary biliary cirrhosis. Hepatol Res. 2007;37 Suppl 3:S406-S411. [PMID: 17931195 DOI: 10.1111/j.1872-034x.2007.00227.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
58 Silveira MG, Brunt EM, Heathcote J, Gores GJ, Lindor KD, Mayo MJ. American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology. 2010;52:349-359. [PMID: 20578151 DOI: 10.1002/hep.23637] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 4.9] [Reference Citation Analysis]
59 Norman GL, Yang CY, Ostendorff HP, Shums Z, Lim MJ, Wang J, Awad A, Hirschfield GM, Milkiewicz P, Bloch DB. Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis. Liver Int. 2015;35:642-651. [PMID: 25243383 DOI: 10.1111/liv.12690] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
60 Milkiewicz P, Buwaneswaran H, Coltescu C, Shums Z, Norman GL, Heathcote EJ. Value of autoantibody analysis in the differential diagnosis of chronic cholestatic liver disease. Clin Gastroenterol Hepatol. 2009;7:1355-1360. [PMID: 19631286 DOI: 10.1016/j.cgh.2009.07.012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
61 Toniutto P, Fabris C, Pirisi M. Antiviral treatment of hepatitis C. Expert Opin Pharmacother 2006;7:2025-35. [PMID: 17020430 DOI: 10.1517/14656566.7.15.2025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
62 Papatheodoridis GV, Cholongitas E. Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options. J Viral Hepat. 2004;11:287-296. [PMID: 15230850 DOI: 10.1111/j.1365-2893.2004.00522.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
63 Lan RY, Cheng C, Lian Z, Tsuneyama K, Yang G, Moritoki Y, Chuang Y, Nakamura T, Saito S, Shimoda S, Tanaka A, Bowlus CL, Takano Y, Ansari AA, Coppel RL, Gershwin ME. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology 2006;43:729-37. [DOI: 10.1002/hep.21123] [Cited by in Crossref: 226] [Cited by in F6Publishing: 198] [Article Influence: 14.1] [Reference Citation Analysis]
64 Yamanaka T, Fukatsu T, Ichinohe Y, Hirata Y. Antimitochondrial antibodies-positive myositis accompanied by cardiac involvement. BMJ Case Rep 2017;2017:bcr2016218469. [PMID: 28363947 DOI: 10.1136/bcr-2016-218469] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
65 Sakauchi F, Oura A, Ohnishi H, Mori M. Comparison of the clinical features of Japanese patients with primary biliary cirrhosis in 1999 and 2004: utilization of clinical data when patients applied to receive public financial aid. J Epidemiol. 2007;17:210-214. [PMID: 18094520 DOI: 10.2188/jea.17.210] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
66 Rigopoulou EI, Dalekos GN. Molecular diagnostics of primary biliary cirrhosis. Expert Opin Med Diagn. 2008;2:621-634. [PMID: 23495774 DOI: 10.1517/17530059.2.6.621] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
67 Shapira Y, Agmon-Levin N, Renaudineau Y, Porat-Katz BS, Barzilai O, Ram M, Youinou P, Shoenfeld Y. Serum markers of infections in patients with primary biliary cirrhosis: evidence of infection burden. Exp Mol Pathol. 2012;93:386-390. [PMID: 23022373 DOI: 10.1016/j.yexmp.2012.09.012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
68 Chen S, Zhu GJ, Deng GH, Zhu Y. Clinical pathology and HLA-DRB1 allele associations of primary biliary cirrhosis and autoimmune cholangitis in Han Chinese. Shijie Huaren Xiaohua Zazhi 2005; 13(20): 2450-2454 [DOI: 10.11569/wcjd.v13.i20.2450] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
69 Gatselis NK, Dalekos GN. Molecular diagnostic testing for primary biliary cholangitis. Expert Review of Molecular Diagnostics 2016;16:1001-10. [DOI: 10.1080/14737159.2016.1217159] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
70 Wang L, Wang J, Shi Y, Zhou X, Wang X, Li Z, Huang X, Wang J, Han Z, Li T, Wang M, Wang R, Fan D, Han Y. Identification of a primary biliary cirrhosis associated protein as lysosome-associated membrane protein-2. Journal of Proteomics 2013;91:569-79. [DOI: 10.1016/j.jprot.2013.08.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
71 Gabeta S, Norman GL, Liaskos C, Papamichalis PA, Zografos T, Garagounis A, Rigopoulou EI, Dalekos GN. Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. J Clin Immunol 2007;27:378-87. [PMID: 17514501 DOI: 10.1007/s10875-007-9092-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 2.8] [Reference Citation Analysis]
72 Ozaslan E. Autoimmune hepatitis-autoimmune cholangitis overlap syndrome and autoimmune thyroiditis in a patient with celiac disease. Eur J Gastroenterol Hepatol. 2009;21:716-718. [PMID: 19436174 DOI: 10.1097/meg.0b013e328308bbaf] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
73 Dong X, Yu X, Li H, Kang H. Identification of Marker Genes and Pathways in Patients with Primary Biliary Cholangitis. J Comput Biol 2020;27:923-33. [PMID: 31638426 DOI: 10.1089/cmb.2019.0230] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
74 Heathcote EJ. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterology 2002;97:1090-2. [DOI: 10.1111/j.1572-0241.2002.05699.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
75 Beuers U. Hepatic overlap syndromes. J Hepatol 2005;42 Suppl:S93-9. [PMID: 15777577 DOI: 10.1016/j.jhep.2004.11.009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 2.0] [Reference Citation Analysis]
76 Glass LM, Su GL. Metabolic Bone Disease in Primary Biliary Cirrhosis. Gastroenterol Clin North Am. 2016;45:333-343. [PMID: 27261902 DOI: 10.1016/j.gtc.2016.02.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
77 Kikuchi K, Lian ZX, Kimura Y, Selmi C, Yang GX, Gordon SC, Invernizzi P, Podda M, Coppel RL, Ansari AA, Ikehara S, Miyakawa H, Gershwin ME. Genetic polymorphisms of toll-like receptor 9 influence the immune response to CpG and contribute to hyper-IgM in primary biliary cirrhosis. J Autoimmun. 2005;24:347-352. [PMID: 15878652 DOI: 10.1016/j.jaut.2005.03.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 3.4] [Reference Citation Analysis]
78 Liu H, Norman GL, Shums Z, Worman HJ, Krawitt EL, Bizzaro N, Vergani D, Bogdanos DP, Dalekos GN, Milkiewicz P. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun. 2010;35:436-442. [PMID: 20932720 DOI: 10.1016/j.jaut.2010.09.005] [Cited by in Crossref: 93] [Cited by in F6Publishing: 85] [Article Influence: 7.8] [Reference Citation Analysis]
79 Rathi S, Dhiman RK. Hepatobiliary Quiz Answers - 18 (2016). J Clin Exp Hepatol 2016;6:159-63. [PMID: 27493465 DOI: 10.1016/j.jceh.2016.06.174] [Reference Citation Analysis]
80 Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, Lindor KD, Kaplan MM, Vierling JM; USA PBC Epidemiology Group. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005;42:1194-202. [PMID: 16250040 DOI: 10.1002/hep.20907] [Cited by in Crossref: 395] [Cited by in F6Publishing: 327] [Article Influence: 23.2] [Reference Citation Analysis]
81 Joshita S, Umemura T, Yoshizawa K, Katsuyama Y, Tanaka E, Nakamura M, Ishibashi H, Ota M; Shinshu PBC Study Group. Association analysis of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with primary biliary cirrhosis in Japanese patients. J Hepatol 2010;53:537-41. [PMID: 20557968 DOI: 10.1016/j.jhep.2010.03.017] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
82 Dähnrich C, Pares A, Caballeria L, Rosemann A, Schlumberger W, Probst C, Mytilinaiou M, Bogdanos D, Vergani D, Stöcker W. New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies. Clin Chem. 2009;55:978-985. [PMID: 19264849 DOI: 10.1373/clinchem.2008.118299] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 4.4] [Reference Citation Analysis]
83 Juliusson G, Imam M, Björnsson ES, Talwalkar JA, Lindor KD. Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis. Scand J Gastroenterol. 2016;51:745-752. [PMID: 26776319 DOI: 10.3109/00365521.2015.1132337] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
84 Trauner M, Boyer JL. Cholestatic syndromes: . Current Opinion in Gastroenterology 2002;18:314-29. [DOI: 10.1097/00001574-200205000-00005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
85 Terjung B, Spengler U. Role of auto-antibodies for the diagnosis of chronic cholestatic liver diseases. Clin Rev Allergy Immunol. 2005;28:115-133. [PMID: 15879618 DOI: 10.1385/criai:28:2:115] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
86 Kikuchi K, Lian ZX, Yang GX, Ansari AA, Ikehara S, Kaplan M, Miyakawa H, Coppel RL, Gershwin ME. Bacterial CpG induces hyper-IgM production in CD27(+) memory B cells in primary biliary cirrhosis. Gastroenterology. 2005;128:304-312. [PMID: 15685542 DOI: 10.1053/j.gastro.2004.11.005] [Cited by in Crossref: 110] [Cited by in F6Publishing: 93] [Article Influence: 6.5] [Reference Citation Analysis]
87 Agmon-Levin N, Shapira Y, Selmi C, Barzilai O, Ram M, Szyper-Kravitz M, Sella S, Katz BS, Youinou P, Renaudineau Y, Larida B, Invernizzi P, Gershwin ME, Shoenfeld Y. A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. J Autoimmun 2010;34:55-8. [PMID: 19897339 DOI: 10.1016/j.jaut.2009.08.009] [Cited by in Crossref: 74] [Cited by in F6Publishing: 62] [Article Influence: 5.7] [Reference Citation Analysis]
88 Zeng N, Duan W, Chen S, Wu S, Ma H, Ou X, You H, Kong Y, Jia J. Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis. Hepatol Int 2019;13:788-99. [PMID: 31552558 DOI: 10.1007/s12072-019-09984-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
89 Jiang XH, Zhong RQ, Yu SQ, Hu Y, Li WW, Kong XT. Construction and expression of a humanized M2 autoantigen trimer and its application in the diagnosis of primary biliary cirrhosis. World J Gastroenterol 2003; 9(6): 1352-1355 [PMID: 12800255 DOI: 10.3748/wjg.v9.i6.1352] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
90 Selmi C, Ichiki Y, Invernizzi P, Podda M, Gershwin ME. The enigma of primary biliary cirrhosis. Clin Rev Allergy Immunol 2005;28:73-81. [PMID: 15879614 DOI: 10.1385/CRIAI:28:2:073] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
91 Eugenia Rinella M. Primary biliary cirrhosis. Annals of Hepatology 2006;5:198-200. [DOI: 10.1016/s1665-2681(19)32010-1] [Reference Citation Analysis]
92 Leung PS, Rossaro L, Davis PA, Park O, Tanaka A, Kikuchi K, Miyakawa H, Norman GL, Lee W, Gershwin ME; Acute Liver Failure Study Group. Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology 2007;46:1436-42. [PMID: 17657817 DOI: 10.1002/hep.21828] [Cited by in Crossref: 83] [Cited by in F6Publishing: 68] [Article Influence: 5.5] [Reference Citation Analysis]
93 Rust C, Beuers U. Overlap syndromes among autoimmune liver diseases. World J Gastroenterol 2008; 14(21): 3368-3373 [PMID: 18528934 DOI: 10.3748/wjg.14.3368] [Cited by in CrossRef: 85] [Cited by in F6Publishing: 78] [Article Influence: 6.1] [Reference Citation Analysis]
94 Oertelt S, Rieger R, Selmi C, Invernizzi P, Ansari AA, Coppel RL, Podda M, Leung PS, Gershwin ME. A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis. Hepatology. 2007;45:659-665. [PMID: 17326160 DOI: 10.1002/hep.21583] [Cited by in Crossref: 113] [Cited by in F6Publishing: 103] [Article Influence: 7.5] [Reference Citation Analysis]
95 Romero-gomez M, Wichmann I, Crespo J, Pares A, Rodrigo L, Alvarez A, Diago M, Pons-romero F, Sanchez-munoz D, Aguilar-reina J, Andrade RJ, Salmeron J, Sanchez-pobre P, Rebollo JM, Martin-vivaldi R, Castellano-megias V, Nunez-roldan A, Bruguera M; Spanish Group for the Study of Autoimmune Cholangitis+. Serum Immunological Profile in Patients with Chronic Autoimmune Cholestasis. Am J Gastroenterology 2004;99:2150-7. [DOI: 10.1111/j.1572-0241.2004.40416.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
96 Pockros PJ. Developments in the treatment of chronic hepatitis C. Expert Opin Investig Drugs 2002;11:515-28. [PMID: 11922860 DOI: 10.1517/13543784.11.4.515] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 1.8] [Reference Citation Analysis]
97 Bargou I, Mankaï A, Jamaa A, Ben Jazia I, Skandrani K, Sfar H, Baccouche A, Ajmi S, Letaief A, Fabien N, Jeddi M, Ghedira I. Detection of M2 antimitochondrial antibodies by dot blot assay is more specific than by enzyme linked immunosorbent assay. Pathologie Biologie 2008;56:10-4. [DOI: 10.1016/j.patbio.2007.05.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
98 Sedlack RE, Smyrk TC, Czaja AJ, Talwalkar JA. Celiac disease-associated autoimmune cholangitis. Am J Gastroenterol. 2002;97:3196-3198. [PMID: 12492211 DOI: 10.1111/j.1572-0241.2002.07131.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
99 Oertelt S, Kenny TP, Selmi C, Invernizzi P, Podda M, Gershwin ME. SNP analysis of genes implicated in T cell proliferation in primary biliary cirrhosis. Clin Dev Immunol 2005;12:259-63. [PMID: 16584111 DOI: 10.1080/17402520500317859] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
100 Ozaslan E, Efe C, Gokbulut Ozaslan N. The diagnosis of antimitochondrial antibody-negative primary biliary cholangitis. Clin Res Hepatol Gastroenterol 2016;40:553-61. [PMID: 27567165 DOI: 10.1016/j.clinre.2016.06.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
101 Worman HJ, Courvalin JC. Antinuclear antibodies specific for primary biliary cirrhosis. Autoimmun Rev. 2003;2:211-217. [PMID: 12848948 DOI: 10.1016/s1568-9972(03)00013-2] [Cited by in Crossref: 68] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
102 Fritzler MJ, Manns MP. Anti-mitochondrial autoantibodies. Clinical and Applied Immunology Reviews 2002;3:87-113. [DOI: 10.1016/s1529-1049(02)00058-2] [Cited by in Crossref: 18] [Article Influence: 0.9] [Reference Citation Analysis]
103 Kadokawa Y, Omagari K, Hazama H, Ohba K, Masuda J, Kinoshita H, Hayashida K, Isomoto H, Mizuta Y, Murase K. Evaluation of newly developed ELISA using "MESACUP-2 test mitochondrial M2" kit for the diagnosis of primary biliary cirrhosis. Clin Biochem. 2003;36:203-210. [PMID: 12726929 DOI: 10.1016/s0009-9120(02)00439-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
104 Barbouche MR, Chen Q, Carbone M, Ben-Mustapha I, Shums Z, Trifa M, Malinverno F, Bernuzzi F, Zhang H, Agrebi N, Norman GL, Chang C, Gershwin ME, Invernizzi P. Comprehensive review of autoantibodies in patients with hyper-IgM syndrome. Cell Mol Immunol 2018;15:610-7. [PMID: 29400703 DOI: 10.1038/cmi.2017.140] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
105 Kikuchi K, Hsu W, Hosoya N, Moritoki Y, Kajiyama Y, Kawai T, Takai A, Hayami E, Selmi C, Gershwin ME, Miyakawa H. Ursodeoxycholic acid reduces CpG-induced IgM production in patients with primary biliary cirrhosis. Hepatology Research 2009;39:448-54. [DOI: 10.1111/j.1872-034x.2008.00474.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
106 Villalta D, Sorrentino MC, Girolami E, Tampoia M, Alessio MG, Brusca I, Daves M, Porcelli B, Barberio G, Bizzaro N. Autoantibody profiling of patients with primary biliary cirrhosis using a multiplexed line-blot assay. Clinica Chimica Acta 2015;438:135-8. [DOI: 10.1016/j.cca.2014.08.024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
107 Ambrosini YM, Yang GX, Zhang W, Tsuda M, Shu S, Tsuneyama K, Leung PS, Ansari AA, Coppel RL, Gershwin ME. The multi-hit hypothesis of primary biliary cirrhosis: polyinosinic-polycytidylic acid (poly I:C) and murine autoimmune cholangitis. Clin Exp Immunol 2011;166:110-20. [PMID: 21910728 DOI: 10.1111/j.1365-2249.2011.04453.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
108 Czaja AJ. Autoantibodies in autoimmune liver disease. Adv Clin Chem. 2005;40:127-164. [PMID: 16355922 DOI: 10.1016/s0065-2423(05)40004-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
109 Oertelt S, Lian ZX, Cheng CM, Chuang YH, Padgett KA, He XS, Ridgway WM, Ansari AA, Coppel RL, Li MO, Flavell RA, Kronenberg M, Mackay IR, Gershwin ME. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol 2006;177:1655-60. [PMID: 16849474 DOI: 10.4049/jimmunol.177.3.1655] [Cited by in Crossref: 187] [Cited by in F6Publishing: 173] [Article Influence: 11.7] [Reference Citation Analysis]
110 Orlien SMS, Ahmed TA, Ismael NY, Berhe N, Lauritzen T, Gundersen SG, Johannessen A. High Seroprevalence of Autoantibodies Typical of Autoimmune Liver Disease in Eastern Ethiopia: Is Chewing of Khat (Catha edulis) a Triggering Factor? Can J Gastroenterol Hepatol 2018;2018:4980597. [PMID: 30675469 DOI: 10.1155/2018/4980597] [Reference Citation Analysis]
111 Han E, Jo SJ, Lee H, Choi AR, Lim J, Jung ES, Oh EJ. Clinical relevance of combined anti-mitochondrial M2 detection assays for primary biliary cirrhosis. Clin Chim Acta 2017;464:113-7. [PMID: 27864100 DOI: 10.1016/j.cca.2016.11.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
112 Tsiakalou V, Tsangaridou E, Polioudaki H, Nifli AP, Koulentaki M, Akoumianaki T, Kouroumalis E, Castanas E, Theodoropoulos PA. Optimized detection of circulating anti-nuclear envelope autoantibodies by immunofluorescence. BMC Immunol 2006;7:20. [PMID: 16956395 DOI: 10.1186/1471-2172-7-20] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
113 Kato T, Miyakawa H, Ishibashi M. Frequency and significance of anti-glutathione S-transferase autoantibody (anti-GST A1-1) in autoimmune hepatitis. Journal of Autoimmunity 2004;22:211-6. [DOI: 10.1016/j.jaut.2004.01.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
114 Leung PS, Choi J, Yang G, Woo E, Kenny TP, Gershwin ME. A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis. Expert Rev Mol Diagn 2016;16:697-705. [PMID: 26953925 DOI: 10.1586/14737159.2016.1164038] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
115 Cheung KS, Seto WK, Fung J, Lai CL, Yuen MF. Epidemiology and Natural History of Primary Biliary Cholangitis in the Chinese: A Territory-Based Study in Hong Kong between 2000 and 2015. Clin Transl Gastroenterol. 2017;8:e116. [PMID: 28858291 DOI: 10.1038/ctg.2017.43] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
116 Giorgini A, Selmi C, Invernizzi P, Podda M, Zuin M, Gershwin ME. Primary biliary cirrhosis: solving the enigma. Ann N Y Acad Sci. 2005;1051:185-193. [PMID: 16126958 DOI: 10.1196/annals.1361.060] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
117 Miyachi K, Hankins RW, Matsushima H, Kikuchi F, Inomata T, Horigome T, Shibata M, Onozuka Y, Ueno Y, Hashimoto E. Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study. J Autoimmun. 2003;20:247-254. [PMID: 12753810 DOI: 10.1016/s0896-8411(03)00033-7] [Cited by in Crossref: 59] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
118 Chuang YH, Lian ZX, Cheng CM, Lan RY, Yang GX, Moritoki Y, Chiang BL, Ansari AA, Tsuneyama K, Coppel RL, Gershwin ME. Increased levels of chemokine receptor CXCR3 and chemokines IP-10 and MIG in patients with primary biliary cirrhosis and their first degree relatives. J Autoimmun. 2005;25:126-132. [PMID: 16243485 DOI: 10.1016/j.jaut.2005.08.009] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 4.2] [Reference Citation Analysis]
119 Wesierska-Gadek J, Penner E, Battezzati PM, Selmi C, Zuin M, Hitchman E, Worman HJ, Gershwin ME, Podda M, Invernizzi P. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology. 2006;43:1135-1144. [PMID: 16628641 DOI: 10.1002/hep.21172] [Cited by in Crossref: 129] [Cited by in F6Publishing: 120] [Article Influence: 8.1] [Reference Citation Analysis]
120 Meda F, Zuin M, Invernizzi P, Vergani D, Selmi C. Serum autoantibodies: a road map for the clinical hepatologist. Autoimmunity. 2008;41:27-34. [PMID: 18176862 DOI: 10.1080/08916930701619227] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
121 Pockros PJ. Current status of immunomodulatory therapies in HCV infection. Curr hepatitis rep 2004;3:16-22. [DOI: 10.1007/s11901-004-0004-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
122 Tsuda M, Zhang W, Yang GX, Tsuneyama K, Ando Y, Kawata K, Park O, Leung PS, Coppel RL, Ansari AA. Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFβ receptor type II mice. Hepatology. 2013;57:806-816. [PMID: 22576253 DOI: 10.1002/hep.25829] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 7.6] [Reference Citation Analysis]
123 Vergani D, Bogdanos D. Positive markers in AMA-negative PBC. Am J Gastroenterology 2003;98:241-3. [DOI: 10.1111/j.1572-0241.2003.07270.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.3] [Reference Citation Analysis]
124 Khan FM, Komarla AR, Mendoza PG, Bodenheimer HC Jr, Theise ND. Keratin 19 demonstration of canal of Hering loss in primary biliary cirrhosis: "minimal change PBC"? Hepatology 2013;57:700-7. [PMID: 22911653 DOI: 10.1002/hep.26020] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
125 Dhirapong A, Lleo A, Yang GX, Tsuneyama K, Dunn R, Kehry M, Packard TA, Cambier JC, Liu FT, Lindor K. B cell depletion therapy exacerbates murine primary biliary cirrhosis. Hepatology. 2011;53:527-535. [PMID: 21274873 DOI: 10.1002/hep.24044] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 4.3] [Reference Citation Analysis]
126 Shimoda S, Miyakawa H, Nakamura M, Ishibashi H, Kikuchi K, Kita H, Niiro H, Arinobu Y, Ono N, Mackay IR, Gershwin ME, Akashi K. CD4 T-cell autoreactivity to the mitochondrial autoantigen PDC-E2 in AMA-negative primary biliary cirrhosis. J Autoimmun 2008;31:110-5. [PMID: 18644699 DOI: 10.1016/j.jaut.2008.05.003] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 4.1] [Reference Citation Analysis]
127 Bogdanos DP, Komorowski L. Disease-specific autoantibodies in primary biliary cirrhosis. Clin Chim Acta. 2011;412:502-512. [PMID: 21185272 DOI: 10.1016/j.cca.2010.12.019] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 5.6] [Reference Citation Analysis]
128 Mchutchison JG, Patel K. Future therapy of hepatitis C. Hepatology 2002;36:S245-52. [DOI: 10.1002/hep.1840360731] [Cited by in Crossref: 41] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
129 Li M, Zheng H, Li T, Gao P, Zhang XL, Liu DW. Cytotoxic T-lymphocyte associated antigen-4 gene polymorphisms and primary biliary cirrhosis: a systematic review. J Gastroenterol Hepatol. 2012;27:1159-1166. [PMID: 22414241 DOI: 10.1111/j.1440-1746.2012.07118.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
130 McFarlane IM, Bhamra MS, Kreps A, Iqbal S, Al-Ani F, Saladini-Aponte C, Grant C, Singh S, Awwal K, Koci K, Saperstein Y, Arroyo-Mercado FM, Laskar DB, Atluri P. Gastrointestinal Manifestations of Systemic Sclerosis. Rheumatology (Sunnyvale). 2018;8. [PMID: 30057856 DOI: 10.4172/2161-1149.1000235] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
131 Carpenter HA, Czaja AJ. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. Clin Liver Dis. 2002;6:685-705. [PMID: 12362575 DOI: 10.1016/s1089-3261(02)00022-3] [Cited by in Crossref: 74] [Cited by in F6Publishing: 17] [Article Influence: 3.9] [Reference Citation Analysis]
132 Heathcote EJ. Treatment Considerations in Patients With Hepatitis C and Cirrhosis: . Journal of Clinical Gastroenterology 2003;37:395-8. [DOI: 10.1097/00004836-200311000-00009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]